MiR-19b-3p accelerates bone loss after spinal cord injury by suppressing osteogenesis via regulating PTEN/Akt/mTOR

Da Liu1, Bo Wang2, Min Qiu1

  • 1Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.

Insights

MicroRNA-19b-3p exacerbates bone loss after spinal cord injury (SCI) by inhibiting osteogenesis. Targeting miR-19b-3p with antagomirs can reverse this bone loss, offering a potential therapeutic strategy.

Area of Science:

  • Biomedical research
  • Molecular biology
  • Skeletal biology

Background:

  • Spinal cord injury (SCI) leads to significant bone loss, impacting patient quality of life.
  • MicroRNA (miRNA) dysfunction is implicated in post-SCI bone loss, but specific mechanisms remain unclear.
  • The role of miR-19b-3p in SCI-induced bone loss requires elucidation.

Purpose of the Study:

  • To investigate the role of the miR-19b-3p/PTEN axis in osteogenesis following SCI.
  • To explore the underlying molecular mechanisms, including autophagy and signaling pathways.

Main Methods:

  • Analysis of miR-19b-3p levels in SCI rat femurs.
  • Overexpression of miR-19b-3p in bone marrow mesenchymal stem cells (BMSCs).
  • Investigation of PTEN, Akt, and mTOR phosphorylation.
  • Assessment of autophagy modulation using rapamycin.
  • Treatment of SCI rats with antagomir-19b-3p.

Main Results:

  • miR-19b-3p levels were elevated in SCI rat femurs with reduced autophagy.
  • Overexpressing miR-19b-3p in BMSCs suppressed osteogenic differentiation by downregulating PTEN and activating Akt/mTOR signaling.
  • Autophagy inhibition was linked to miR-19b-3p's suppressive effect on osteogenesis.
  • Rapamycin treatment mitigated the inhibitory effects of miR-19b-3p.
  • Antagomir-19b-3p administration reversed bone loss in SCI rats.

Conclusions:

  • miR-19b-3p promotes bone loss post-SCI by inhibiting osteogenesis.
  • The miR-19b-3p/PTEN/Akt/mTOR pathway regulates osteogenic differentiation via autophagy.
  • miR-19b-3p is a potential therapeutic target for treating bone loss after SCI.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K